|
1
Roth G. A., Forouzanfar M. H., Moran A. E., et al. Demographic and Epidemiologic Drivers of Global Cardiovascular Mortality. New England Journal of Medicine. 2015;372:1333–41.
2
Benjamin E. J., Virani S. S., Callaway C. W., et al. Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. Circulation. 2018;137: e67-e492.
3
Van Norman G. A. Overcoming the Declining Trends in Innovation and Investment in Cardiovascular Therapeutics: Beyond EROOM’s Law. JACC: Basic to Translational Science. 2017;2:613–25.
4
Fordyce C. B., Roe M. T., Ahmad T., et al. Cardiovascular Drug Development: Is It Dead or Just Hibernating? Journal of the American College of Cardiology. 2015;65:1567–82.
5
Stockmann C., Hersh A. L., Sherwin C. M., Spigarelli M. G. Alignment of United States Funding for Cardiovascular Disease Research with Deaths, Years of Life Lost, and Hospitalizations. International Journal of Cardiology. 2014;172: e19–21.
6
Berry T. R., Stearns J. A., Courneya K. S., et al. Women’s Perceptions of Heart Disease and Breast Cancer and the Association with Media Representations of the Diseases. Journal of Public Health (Oxford). 2016;38: e496-e503.
7
Gunderman R. Illness as Failure. Blaming Patients. Hastings Center Report. 2000;30:7–11.
8
Vaughan A. S., Ritchey M. D., Hannan J., Kramer M. R., Casper M. Widespread Recent Increases in County-Level Heart Disease Mortality Across Age Groups. Annals of Epidemiology. 2017;27:796–800.
9
Van der Linde D., Konings E. E., Slager M. A., et al. Birth Prevalence of Congenital Heart Disease Worldwide: A Systematic Review and Meta-Analysis. Journal of the American College of Cardiology. 2011;58:2241–7.
10
Hoffman J. I., Kaplan S. The Incidence of Congenital Heart Disease. Journal of the American College of Cardiology. 2002;39:1890–900.
11
National Wildlife Foundation. Animals Really Do Have Heart. http://blog.nwf.org/2013/02/amazing-animal-hearts/.
12
Woods H. A., Lane S. J., Shishido C., Tobalske B. W., Arango C. P., Moran A. L. Respiratory Gut Peristalsis by Sea Spiders. Current Biology. 2017;27: R638–9.
13
Ross J., Jr., Braunwald E. Aortic Stenosis. Circulation. 1968;38:61–7.
14
Cribier A., Savin T., Saoudi N., Rocha P., Berland J., Letac B. Percutaneous Transluminal Valvuloplasty of Acquired Aortic Stenosis in Elderly Patients: An Alternative to Valve Replacement? Lancet. 1986;1:63–7.
15
Cribier A., Eltchaninoff H., Bash A., et al. Percutaneous Transcatheter Implantation of an Aortic Valve Prosthesis for Calcific Aortic Stenosis: First Human Case Description. Circulation. 2002;106:3006–8.
16
Osler W. The Evolution of Modern Medicine. New Haven: Yale University Press; 1921.
17
Sprunt W. H. Imhotep. New England Journal of Medicine. 1955;253:778–80.
18
Haas L. F. Papyrus of Ebers and Smith. Journal of Neurology, Neurosurgery, and Psychiatry. 1999;67:578.
19
Sprunt. Imhotep.
20
Willerson J. T., Teaff R. Egyptian Contributions to Cardiovascular Medicine. Texas Heart Institute Journal. 1996;23:191–200.
21
Boisaubin E. V. Cardiology in Ancient Egypt. Texas Heart Institute Journal. 1988;15:80–5.
22
Saba M. M., Ventura H. O., Saleh M., Mehra M. R. Ancient Egyptian Medicine and the Concept of Heart Failure. Journal of Cardiac Failure. 2006;12:416–21.
23
Heberden W. Some Account of Disorder of the Breast. Medical Transactions. The Royal College of Physicians of London. 1772;2:59–67.
24
Hajar R. Coronary Heart Disease: From Mummies to 21st Century. Heart Views. 2017;18:68–74.
25
Saba, Ventura, Saleh, Mehra. Ancient Egyptian Medicine.
26
Ritner RK. The Cardiovascular System in Ancient Egyptian Thought. Journal of Near Eastern Studies. 2006;65:99–109.
27
Arikha N. Passion and Tempers: A History of the Humors. New York: Ecco; 2007.
28
Ranhel A. S., Mesquita ET. The Middle Ages Contributions to Cardiovascular Medicine. Brazilian Journal of Cardiovascular Surgery. 2016;31:163–70.
29
Masic I. On Occasion of 800th Anniversary of Birth of Ibn al-Nafis – Discoverer of Cardiac and Pulmonary Circulation. Medical Archives. 2010;64:309–13.
30
Abdel-Halim R. E. The Role of Ibn Sina (Avicenna)’s Medical Poem in the Transmission of Medical Knowledge to Medieval Europe. Urology Annals. 2014;6:1–12.
31
Loukas M., Lam R., Tubbs R. S., Shoja M. M., Apaydin N. Ibn al-Nafis (1210–1288): The First Description of the Pulmonary Circulation. American Surgeon. 2008;74:440–2.
32
West J. B. Ibn al-Nafis, the Pulmonary Circulation, and the Islamic Golden Age. Journal of Applied Physiology. 2008;105:1877–80.
33
Aird W. C. Discovery of the Cardiovascular System: From Galen to William Harvey. Journal of Thrombosis and Haemostasis. 2011;9 Suppl 1:118–29.
34
Òàì æå.
35
Osler W. Tercentenary of the Death of William Harvey 1. The Growth of Truth. British Medical Journal. 1957;1:8 1–1263.
36
Lubitz S. A. Early Reactions to Harvey’s Circulation Theory: The Impact on Medicine. Mount Sinai Journal of Medicine. 2004;71:274–80.
37
French R. William Harvey’s Natural Philosophy. Cambridge, UK: Cambridge University Press; 1994.
38
Lubitz. Early Reactions.
39
Erickson R. The Language of the Heart, 1600–1750. Philadelphia, PA: University of Pennsylvania Press 1997.
40
Benjamin E. J., Virani S. S., Callaway C. W., et al. Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. Circulation. 2018;137: e67-e492.
41
President Eisenhower’s $14 Billion Heart Attack. 2016. www.ozy.com/flashback/president-eisenhowers-14-billion-heart-attack/65157.
42
Lasby C. G. Eisenhower’s Heart Attack: How Ike Beat Heart Disease and Held On to the Presidency. Lawrence, KS: University Press of Kansas; 1997.
43
Bentzon J.F, Otsuka F., Virmani R., Falk E. Mechanisms of Plaque Formation and Rupture. Circulation Research. 2014;114:1852–66.
44
Strong J. P., Malcom G. T., McMahan C.A., et al. Prevalence and Extent of Atherosclerosis in Adolescents and Young Adults: Implications for Prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. Journal of the American Medical Association. 1999;281:727–35.
45
Giuseppe Zoccai, Mariangela Peruzzi, Enrico Romagnoli. Is the Pathophysiology of Plaque Injury in Acute MI Changing? Revisiting Plaque Erosion vs. Rupture. 2016. www.acc.org/latest-in-cardiology/articles/2016/02/26/09/34/is-the-pathophysiology-of-plaque-injury-in-acute-mi-changing.
46
Stefanadis C., Antoniou C. K., Tsiachris D., Pietri P. Coronary Atherosclerotic Vulnerable Plaque: Current Perspectives. Journal of the American Heart Association. 2017;6.
47
Milton K. Back to Basics: Why Foods of Wild Primates Have Relevance for Modern Human Health. Nutrition. 2000;16:480–3.
48
Pijl H. Obesity: Evolution of a Symptom of Affluence. Netherlands Journal of Medicine. 2011;69:159–66.
49
Fish J. L., Lockwood C. A. Dietary Constraints on Encephalization in Primates. American Journal of Physical Anthropology. 2003;120:171–81.
50
The Oldest Homo Sapiens Yet. Economist. June 10, 2017.
51
Neel J. V. Diabetes Mellitus: a “Thrifty” Genotype Rendered Detrimental by “Progress”? American Journal of Human Genetics. 1962;14:353–62.
52
Stern M. P. Diabetes and Cardiovascular Disease. The “Common Soil” Hypothesis. Diabetes. 1995;44:369–74.
53
Fernandez-Real J.M., Ricart W. Insulin Resistance and Inflammation in an Evolutionary Perspective: The Contribution of Cytokine Genotype/Phenotype to Thriftiness. Diabetologia. 1999;42:1367–74.
54
Wells J. C. Ethnic Variability in Adiposity and Cardiovascular Risk: The Variable Disease Selection Hypothesis. International Journal of Epidemiology. 2009;38:63–71.
55
Warraich H. J., Javed F., Faraz-Ul-Haq M., Khawaja F.B, Saleem S. Prevalence of Obesity in School-Going Children of Karachi. PLOS ONE. 2009;4: e4816.
56
Thomas G.S, Wann L.S, Allam A. H., et al. Why Did Ancient People Have Atherosclerosis?: From Autopsies to Computed Tomography to Potential Causes. Global Heart. 2014;9:229–37.
57
Keller A., Graefen A., Ball M., et al. New Insights into the Tyrolean Iceman’s Origin and Phenotype as Inferred by Whole-Genome Sequencing. Nature Communications. 2012;3:698.
58
Ruffer M. A. On Arterial Lesions Found in Egyptian Mummies (1580 BC-525 AD). Journal of Pathology and Bacteriology. 1911;15.
59
Thompson R.C, Allam A.H, Lombardi G. P., et al. Atherosclerosis Across 4000 Years of Human History: The Horus Study of Four Ancient Populations. Lancet. 2013;381:1211–22.
60
Death Rates for 1911 in the United States and its Large Cities. Boston Medical and Surgical Journal. 1912; CLXVI:63–4.
61
Gurven M., Stieglitz J., Trumble B., et al. The Tsimane Health and Life History Project: Integrating anthropology and biomedicine. Evolutionary Anthropology. 2017;26:54–73.
62
Packard R. R., Libby P. Inflammation in Atherosclerosis: From Vascular Biology to Biomarker Discovery and Risk Prediction. Clinical Chemistry. 2008;54:24–38.
63
Shaharyar S., Warraich H., McEvoy J.W., et al. Subclinical Cardiovascular Disease in Plaque Psoriasis: Association or Causal Link? Atherosclerosis. 2014;232:72–8.
64
Hemkens L. G., Ewald H., Gloy V. L., et al. Colchicine for Prevention of Cardiovascular Events. Cochrane Database of Systematic Reviews. 2016: CD011047.
65
De Vecchis R., Baldi C., Palmisani L. Protective Effects of Methotrexate Against Ischemic Cardiovascular Disorders in Patients Treated for Rheumatoid Arthritis or Psoriasis: Novel Therapeutic Insights Coming from a Meta-Analysis of the Literature Data. Anatolian Journal of Cardiology. 2016;16:2–9.
66
Ridker P. M., Everett B. M., Thuren T., et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. New England Journal of Medicine. 2017;377:1119–31.
67
Lerner B. H. Crafting Medical History: Revisiting the “Definitive” Account of Franklin D. Roosevelt’s Terminal Illness. Bulletin of the History of Medicine. 2007;81:386–406.
68
Bruenn H. G. Clinical Notes on the Illness and Death of President Franklin D. Roosevelt. Annals of Internal Medicine. 1970;72:579–91.
69
Pinals R. S., Smulyan H. The death of President Warren G. Harding. American Journal of the Medical Sciences. 2014;348:232–7.
70
Chen G., Levy D. Contributions of the Framingham Heart Study to the Epidemiology of Coronary Heart Disease. JAMA Cardiology. 2016;1:825–30.
71
Mahmood S. S., Levy D., Vasan R. S., Wang T. J. The Framingham Heart Study and the Epidemiology of Cardiovascular Disease: A Historical Perspective. Lancet. 2014;383:999–1008.
72
Dawber T. R., Moore F. E., Mann G. V. Coronary Heart Disease in the Framingham Study. American Journal of Public Health and the Nation’s Health. 1957;47:4–24.
73
Kannel W. B., Dawber T. R., Kagan A., Revotskie N., Stokes J., 3rd. Factors of Risk in the Development of Coronary Heart Disease – Six Year Follow-Up Experience. The Framingham Study. Annals of Internal Medicine. 1961;55:33–50.
74
Rakotz M. K., Townsend R. R., Yang J., et al. Medical Students and Measuring Blood Pressure: Results from the American Medical Association Blood Pressure Check Challenge. Journal of Clinical Hypertension (Greenwich), 2017;19:614–9.
75
Frieden T. R. Shattuck Lecture: The Future of Public Health. New England Journal of Medicine. 2015;373:1748–54.
76
Sotos J. G. President Taft’s Blood Pressure. Mayo Clinic Proceedings. 2006;81:1507–8.
77
Menger R. P., Storey C. M., Guthikonda B., Missios S, Nanda A, Cooper JM. Woodrow Wilson’s Hidden Stroke of 1919: The Impact of Patient-Physician Confidentiality on United States Foreign Policy. Neurosurgical Focus. 2015;39: E6.
78
Steinberg D. President Franklin D Roosevelt (1882–1945) and Doctor Frank Howard Lahey’s (1880–1953) Dilemma: The Complexities of Medical Confidentiality with World Leaders. Journal of Medical Biography. 2016;24:50–60.
79
Osler W. An Address on High Blood Pressure: Its Associations, Advantages, and Disadvantages: Delivered at the Glasgow Southern Medical Society. British Medical Journal. 1912;2:1173–7.
80
White P. D. Heart Disease. 2nd ed. New York: MacMillan Co; 1937:326.
81
Hay J. A British Medical Association Lecture on the Significance of a Raised Blood Pressure. British Medical Journal. 1931;2:43–7.
82
Fisher J. W. The Diagnostic Value of the Sphygmomanometer in Examinations for Life Insurance. Journal of the American Medical Association. 1914;63:1752–54.
83
Society of Actuaries. Blood Pressure: Report of the Joint Committee on Mortality of the Association of Life Insurance Medical Directors and the Actuarial Society of America. New York:1925.
84
Dawber, Moore, Mann. Coronary Heart Disease.
85
Kannel W. B., Dawber T. R., Cohen M. E., McNamara P. M. Vascular Disease of the Brain – Epidemiologic Aspects: The Framingham Study. American Journal of Public Health and the Nation’s Health. 1965;55:1355–66.
86
Kannel W. B. Bishop Lecture. Contribution of the Framingham Study to Preventive Cardiology. Journal of the American College of Cardiology. 1990;15:206–11.
87
Kolata G. Lower Blood Pressure Guidelines Could Be “Lifesaving,” Federal Study Says. New York Times. September 11, 2015.
88
Muntner P., Carey R. M., Gidding S., et al. Potential US Population Impact of the 2017 ACC/AHA High Blood Pressure Guideline. Circulation. 2018;137:109–18.
89
Frieden. Shattuck Lecture.
90
Bruenn. Clinical Notes.
91
Morris M. J., Na E. S., Johnson A. K. Salt Craving: The Psychobiology of Pathogenic Sodium Intake. Physiology & Behavior. 2008;94:709–21.
92
Tekol Y. Salt Addiction: A Different Kind of Drug Addiction. Medical Hypotheses. 2006;67:1233–4.
93
Mozaffarian D., Fahimi S., Singh G. M., et al. Global Sodium Consumption and Death from Cardiovascular Causes. New England Journal of Medicine. 2014;371:624–34.
94
United Nations Office on Drugs and Crime, World Drug Report 2017 (ISBN: 978–92–1–148291–1, eISBN: 978–92–1–060623–3, United Nations publication, Sales No. E.17.XI.6).
95
Campbell NRC, Train E. J. A Systematic Review of Fatalities Related to Acute Ingestion of Salt. A Need for Warning Labels? Nutrients. 2017;9.
96
Hedouin V., Revuelta E., Becart A., Tournel G., Deveaux M., Gosset D. A Case of Fatal Salt Water Intoxication Following an Exorcism Session. Forensic Science International. 1999;99:1–4.
97
Ofran Y., Lavi D., Opher D., Weiss T. A., Elinav E. Fatal Voluntary Salt Intake Resulting in the Highest Ever Documented Sodium Plasma Level in Adults (255 mmol L-1): A Disorder Linked to Female Gender and Psychiatric Disorders. Journal of Internal Medicine. 2004;256:525–8.
98
Draft Guidance for Industry: Voluntary Sodium Reduction Goals: Target Mean and Upper Bound Concentrations for Sodium in Commercially Processed, Packaged, and Prepared Foods. June 2016. www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/ucm494732.htm.
99
Jackson S. L., King S. M., Zhao L., Cogswell M. E. Prevalence of Excess Sodium Intake in the United States-NHANES, 2009–2012. Morbidity and Mortality Weekly Report. 2016;64:1393–7.
100
American Heart Association Sodium Reduction Initiative Team. The Salty Six – Surprising Foods that Add the Most Sodium to our Diets. 2014. https://sodiumbreakup.heart.org/salty-six-surprising-foods-add-sodium-diets/.
101
Mente A., O’Donnell M., Rangarajan S., et al. Associations of Urinary Sodium Excretion with Cardiovascular Events in Individuals with and without Hypertension: A Pooled Analysis of Data from Four Studies. Lancet. 2016;388:465–75.
102
Has Salt Gotten an Unfair Shake? September 3, 2017. www.npr.org/sections/healthshots/2017/09/03/547827356/has-salt-gotten-an-unfair-shake-sodium-partisanssay-yes.
103
Jerusalem Talmud, Horeyot 3:5.
104
Berman LB. Harry Goldblatt: 1891–1977. Journal of the American Medical Association. 1977;238:1846.
105
Downey P. Profile of Sérgio Ferreira. Proceedings of the National Academy of Sciences of the United States of America. 2008;105:19035–7.
106
Patlak M. From Viper’s Venom to Drug Design: Treating Hypertension. FASEB Journal. 2004;18:421.
107
Johns E. J., Kopp U. C., DiBona G. F. Neural Control of Renal Function. Comprehensive Physiology. 2011;1:731–67.
108
Barnett H. J., Jackson M. V., Spaulding W. B. Thiocyanate Psychosis. Journal of the American Medical Association. 1951;147:1554–8.
109
Newcombe C. P., Shucksmith H. S., Suffern W. S. Sympathectomy for Hypertension; Follow-Up of 212 Patients. British Medical Journal. 1959;1:142–4.
110
Symplicity HTNI, Esler M. D., Krum H., et al. Renal Sympathetic Denervation in Patients with Treatment-Resistant Hypertension (The Symplicity HTN-2 Trial): A Randomised Controlled Trial. Lancet. 2010;376:1903–9.
111
Bhatt D. L., Kandzari D. E., O’Neill W.W., et al. A Controlled Trial of Renal Denervation for Resistant Hypertension. New England Journal of Medicine. 2014;370:1393–401.
112
Nes W. D. Biosynthesis of Cholesterol and Other Sterols. Chemical Reviews. 2011;111:6423–51.
113
Rifkind B. Drug Treatment of Hyperlipidemia. Boca Raton, FL: CRC Press; 1991.
114
Thoraco-Abdominal Aorta: Surgical and Anesthetic Management. Edited by Roberto Chiesa, Germano Melissano, Alberto Zangrillo. Milan: Springer Science & Business Media, 2011.
115
Stamler J. Lectures on Preventive Cardiology. New York: Grune & Stratton, Inc.; 1967.
116
Virchow R. Cellular Pathology as Based Upon Physiological and Pathological Histology. Philadelphia: JB Lippincott; 1863.
117
Benlian P. Genetics of Dyslipidemia. Milan: Springer Science & Business Media; 2001.
118
Konstantinov I. E., Mejevoi N., Anichkov N. M. Nikolai N. Anichkov and His Theory of Atherosclerosis. Texas Heart Institute Journal. 2006;33:417–23.
119
Vanitallie T. B. Ancel Keys: A Tribute. Nutrition & Metabolism (London). 2005;2:4.
120
Brozek J. Bibliographical Note on Behavioral Aspects: On the Margin of the 50th Anniversary of the Minnesota Starvation-Nutritional Rehabilitation Experiment. Perceptual Motor Skills. 1995;81:395–400.
121
Keys A. Human Atherosclerosis and the Diet. Circulation. 1952;5:115–8.
122
Keys A. Coronary heart disease in seven countries. 1970. Nutrition. 1997;13:250–2; discussion 49, 3.
123
Marmot M. G., Syme S. L. Acculturation and Coronary Heart Disease in Japanese-Americans. American Journal of Epidemiology. 1976;104:225–47.
124
Dayton S., Pearce M. L., Goldman H., et al. Controlled Trial of a Diet High in Unsaturated Fat for Prevention of Atherosclerotic Complications. Lancet. 1968;2:1060–2.
125
Miettinen M., Turpeinen O., Karvonen M. J., Elosuo R., Paavilainen E. Effect of Cholesterol-Lowering Diet on Mortality from Coronary Heart-Disease and Other Causes. A Twelve-Year Clinical Trial in Men and Women. Lancet. 1972;2:835–8.
126
Demaret K., Weinraub, J. Dr. George Mann Says Low Cholesterol Diets Are Useless, but the “Heart Mafia” Disagrees. People. January 22, 1979.
127
Mann G. V. Diet-Heart: End of an Era. New England Journal of Medicine. 1977;297:644–50.
128
Dietary Fat and Its Relation to Heart Attacks and Strokes. Report by the Central Committee for Medical and Community Program of the American Heart Association. Journal of the American Medical Association. 1961;175:389–91.
129
McMichael J. Fats and Atheroma: an Inquest. British Medical Journal. 1979;1:173–5.
130
Steinberg D. The Pathogenesis of Atherosclerosis. An Interpretive History of the Cholesterol Controversy, Part IV: The 1984 Coronary Primary Prevention Trial Ends It – Almost. Journal of Lipid Research. 2006;47:1–14.
131
The Lipid Research Clinics Coronary Primary Prevention Trial Results. II. The Relationship of Reduction in Incidence of Coronary Heart Disease to Cholesterol Lowering. Journal of the American Medical Association. 1984;251:365–74.
132
Mann G. Coronary Heart Disease–“Doing the Wrong Thing.” Nutrition Today. 1985:12–4.
133
Endo A. A Historical Perspective on the Discovery of Statins. Proceedings of the Japan Academy Series B – Physical and Biological Sciences. 2010;86:484–93.
134
Òàì æå.
135
Stossel T. P. The Discovery of Statins. Cell. 2008;134:903–5.
136
Pedersen T. R., Kjekshus J., Berg K., et al. Randomized Trial of Cholesterol-Lowering in 4444 Patients with Coronary Heart Disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–9.
137
Tang J. L., Armitage J. M., Lancaster T., Silagy C. A., Fowler G. H., Neil HAW. Systematic Review of Dietary Intervention Trials to Lower Blood Total Cholesterol in Free-Living Subjects. British Medical Journal. 1998;316:1213–9.
138
Bhattarai N., Prevost A. T., Wright A. J., Charlton J., Rudisill C., Gulliford MC. Effectiveness of Interventions to Promote Healthy Diet in Primary Care: Systematic Review and Meta-Analysis of Randomised Controlled Trials. BMC Public Health. 2013;13.
139
Collins R., Reith C., Emberson J, et al. Interpretation of the Evidence for the Efficacy and Safety of Statin Therapy. Lancet. 2016;388:2532–61.
140
Salami JA, Warraich H., Valero-Elizondo J, et al. National Trends in Statin Use and Expenditures in the US Adult Population From 2002 to 2013 Insights from the Medical Expenditure Panel Survey. JAMA Cardiology. 2017;2:56–65.
141
Warraich H. J., Salami J. A., Khera R., Valero-Elizondo J, Okunrintemi V, Nasir K. Trends in Use and Expenditures of Brand-Name Atorvastatin After Introduction of Generic Atorvastatin. JAMA Internal Medicine. 2018;178:719–21.
142
Warraich H. The Measles Outbreak Coming Near You. Wall Street Journal. December 3, 2014.
143
Collins, Reith, Emberson, et al. Interpretation of the Evidence.
144
Cohen J. D., Brinton EA, Ito MK, Jacobson TA. Understanding Statin Use in America and Gaps in Patient Education (USAGE): An Internet-Based Survey of 10,138 Current and Former Statin Users. Journal of Clinical Lipidology. 2012;6:208–15.
145
Bruckert E, Hayem G, Dejager S., Yau C., Begaud B. Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients – The PRIMO Study. Cardiovascular Drugs Therapy. 2005;19:403–14.
146
Finegold J. A., Manisty CH, Goldacre B, Barron AJ, Francis DP. What Proportion of Symptomatic Side Effects in Patients Taking Statins Are Genuinely Caused by the Drug? Systematic Review of Randomized Placebo-Controlled Trials to Aid Individual Patient Choice. European Journal of Preventative Cardiology. 2014;21:464–74.
147
Gupta A., Thompson D., Whitehouse A., et al. Adverse Events Associated with Unblinded, but Bot with Blinded, Statin Therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): A Randomised Double-Blind Placebo-Controlled Trial and Its Non-Randomised Non-Blind Extension Phase. Lancet. 2017;389:2473–81.
148
Price D. D., Finniss D. G., Benedetti F. A Comprehensive Review of the Placebo Effect: Recent Advances and Current Thought. Annual Review of Psychology. 2008;59:565–90.
149
Kaptchuk T. J., Miller F. G. Placebo Effects in Medicine. New England Journal of Medicine. 2015;373:8–9.
150
Simpson S. H., Eurich D. T., Majumdar S. R., et al. A Meta-Analysis of the Association Between Adherence to Drug Therapy and Mortality. British Medical Journal. 2006;333:15.
151
Kam-Hansen S., Jakubowski M., Kelley J. M., et al. Altered Placebo and Drug Labeling Changes the Outcome of Episodic Migraine Attacks. Science Translational Medicine. 2014;6:218ra5.
152
Colloca L. Nocebo Effects Can Make You Feel Pain. Science. 2017;358:44.
153
Barron A. J., Zaman N, Cole G. D., Wensel R, Okonko D. O., Francis D. P. Systematic Review of Genuine versus Spurious Side-Effects of Beta-Blockers in Heart Failure Using Placebo Control: Recommendations for Patient Information. International Journal of Cardiology. 2013;168:3572–9.
154
Yusuf S. Why Do People Not Take Life-Saving Medications? The Case of Statins. Lancet. 2016;388:943–5.
155
Serban M. C., Colantonio L. D., Manthripragada A. D., et al. Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction. Journal of the American College of Cardiology. 2017;69:1386–95.
156
Selva-O’Callaghan A., Alvarado-Cardenas M., Pinal-Fernandez I., et al. Statin-Induced Myalgia and Myositis: An Update on Pathogenesis and Clinical Recommendations. Expert Review of Clinical Immunology. 2018;14:215–24.
157
Levy A. Pill Culture Pops. New York. June 9, 2003.
158
Warraich H. J., Schulman K. A. Health Care Tax Inversions – Robbing Both Peter and Paul. New England Journal of Medicine. 2016;374:1005–7.
159
Warraich, Salami, Khera, Valero-Elizondo, Okunrintemi, Nasir. Trends in Use.
160
Jack J. L. Triumph of the Heart: The Story of Statins. Oxford, UK: Oxford University Press; 2009.
161
Salami J. A., Warraich H. J., Valero-Elizondo J., et al. National Trends in Nonstatin Use and Expenditures Among the U. S. Adult Population From 2002 to 2013: Insights From Medical Expenditure Panel Survey. Journal of the American Heart Association. 2018;7.
162
Fredrickson D. S., Altrocchi, P.H., Avioli, L.V, Goodman, D, Goodman, HS. Tangier Disease: Combined Clinical Staff Conference at the National Institutes of Health. Annals of Internal Medicine. 1961:1016–31.
163
Gordon D. J., Probstfield J. L., Garrison R. J., et al. High-Density Lipoprotein Cholesterol and Cardiovascular Disease. Four Prospective American Studies. Circulation. 1989;79:8–15.
164
Forey B. A., Fry J. S., Lee P. N., Thornton A. J., Coombs K. J. The Effect of Quitting Smoking on HDL–Cholesterol – A Review Based on Within-Subject Changes. Biomarker Research. 2013;1:26.
165
Kodama S., Tanaka S., Saito K., et al. Effect of Aerobic Exercise Training on Serum Levels of High-Density Lipoprotein Cholesterol: A Meta-Analysis. Archives of Internal Medicine. 2007;167:999–1008.
166
Berryman C. E., Fleming J. A., Kris-Etherton P. M. Inclusion of Almonds in a Cholesterol-Lowering Diet Improves Plasma HDL Subspecies and Cholesterol Efflux to Serum in Normal-Weight Individuals with Elevated LDL Cholesterol. Journal of Nutrition. 2017;147:1517–23.
167
Investigators A.-H., Boden W. E., Probstfield J.L, et al. Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. New England Journal of Medicine. 2011;365:2255–67.
168
Group HTC, Landray M. J., Haynes R., et al. Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients. New England Journal of Medicine. 2014;371:203–12.
169
Marz W., Kleber M. E., Scharnagl H., et al. HDL Cholesterol: Reappraisal of Its Clinical Relevance. Clinical Research in Cardiology. 2017;106:663–75.
170
Group HTRC, Bowman L., Hopewell J. C., et al. Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. New England Journal of Medicine. 2017;377:1217–27.
171
Voight B. F., Peloso G. M., Orho-Melander M., et al. Plasma HDL Cholesterol and Risk of Myocardial Infarction: A Mendelian Randomisation Study. Lancet. 2012;380:572–80.
172
Khera A. V., Cuchel M., de la Llera-Moya M., et al. Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and Atherosclerosis. New England Journal of Medicine. 2011;364:127–35.
173
Pew Research Center. Public Trust in Government Remains Near Historic Lows as Partisan Attitudes Shift. May 2017. www.people-press.org/2017/05/03/publictrust-in-government-remains-near-historic-lows-as-partisan-attitudes-shift/.
174
Gallup. Americans’ Trust in Mass Media Sinks to New Low. September 2016. https://news.gallup.com/poll/195542/americans-trust-mass-media-sinks-newlow.aspx.
175
Pew Research Center. Public Confidence in Scientists Has Remained Stable for Decades. April 2017. www.pewresearch.org/fact-tank/2017/04/06/public-confidence-in-scientists-has-remained-stable-for-decades/.
176
Huffington Post. People Who Have Sex Four or More Times a Week Make More Money. August 2013. www.huffingtonpost.com/2013/08/14/more-sex-higherwages_n_3755271.html.
177
Moyer M. W. It’s Not Dementia, It’s Your Heart Medication: Cholesterol Drugs and Memory. Scientific American. September 2010.
178
Yusuf S. Why Do People Not Take Life-Saving Medications? The Case of Statins. Lancet. 2016;388:943–5.
179
Are Statins a Key to Preventing Alzheimer’s Disease? December 2016. www.cnn.com/2016/12/12/health/statins-alzheimers-disease/index.html.
180
Canetto S. S., Sakinofsky I. The Gender Paradox in Suicide. Suicide and Life-Threatening Behavior. 1998;28:1–23.
181
Spurious Correlations. www.tylervigen.com/spurious-correlations.
182
Norton B. J. Karl Pearson and Statistics: The Social Origins of Scientific Innovation. Social Studies of Science. 1978;8:3–34.
183
Kalantar-Zadeh K., Block G., Horwich T., Fonarow G. C. Reverse Epidemiology of Conventional Cardiovascular Risk Factors in Patients with Chronic Heart Failure. Journal of the American College of Cardiology. 2004;43:1439–44.
184
Ravnskov U., Diamond D. M., Hama R., et al. Lack of an Association or an Inverse Association Between Low-Density-Lipoprotein Cholesterol and Mortality in the Elderly: A Systematic Review. British Medical Journal. Open 2016;6: e010401.
185
Collier R. Legumes, Lemons and Streptomycin: A Short History of the Clinical Trial. Canadian Medical Association Journal. 2009;180:23–4.
186
Zetterstrom R. Nobel Prize 1937 to Albert von Szent-Gyorgyi: Identification of Vitamin C as the Anti-Scorbutic Factor. Acta Paediatrica. 2009;98:915–9.
187
Moffet H. H. Sham Acupuncture May Be as Efficacious as True Acupuncture: A Systematic Review of Clinical Trials. Journal of Alternative and Complementary Medicine. 2009;15:213–6.
188
Haygarth J. Of the Imagination as a Cause and as a Cure of Disorders of the Body. Bath, UK: R. Cruttwell; 1800.
189
DiMasi J.A., Grabowski H. G., Hansen R. W. Innovation in the Pharmaceutical Industry: New Estimates of R&D Costs. Journal of Health Economics. 2016;47:20–33.
190
Spitz V. Doctors from Hell: The Horrific Account of Nazi Experiments on Humans. Boulder, CO: Sentient Publications; 2005.
191
Berger R. L. Nazi Science – The Dachau Hypothermia Experiments. New England Journal of Medicine. 1990;322:1435–40.
192
Bachrach S. In the Name of Public Health – Nazi Racial Hygiene. New England Journal of Medicine. 2004;351:417–20.
193
Emanuel E. J. The History of Euthanasia Debates in the United States and Britain. Annals of Internal Medicine. 1994;121:793–802.
194
Beecher H. K. Ethics and Clinical Research. New England Journal of Medicine. 1966;274:1354–60.
195
Òàì æå.
196
Òàì æå.
197
Editorial. Sterilization and Its Possible Accomplishments. New England Journal of Medicine. 1934;211:379–80.
198
Brandt A. M. Racism and Research: The Case of the Tuskegee Syphilis Study. Hastings Center Report. 1978;8:21–9.
199
Heller J. Syphilis Victims in U. S. Study Went Untreated for 40 Years. New York Times. July 26, 1972.
200
Kaplan S. Dr. Irwin Schatz, the First, Lonely Voice against Infamous Tuskegee Study, Dies at 83. Washington Post. April 20, 2015.
201
Nanna M. G., Navar A. M., Zakroysky P… et al. Association of Patient Perceptions of Cardiovascular Risk and Beliefs on Statin Drugs with Racial Differences in Statin Use: Insights From the Patient and Provider Assessment of Lipid Management Registry. JAMA Cardiology. 2018.
202
Pitt B, Pfeffer MA, Assmann S. F., et al. Spironolactone for Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine. 2014;370:1383–92.
203
de Denus S., O’Meara E., Desai A. S., et al. Spironolactone Metabolites in TOPCAT New Insights into Regional Variation. New England Journal of Medicine. 2017;376:1690–2.
204
Chavalarias D., Wallach J. D., Li A. H., Ioannidis J. P. Evolution of Reporting P Values in the Biomedical Literature, 1990–2015. Journal of the American Medical Association. 2016;315:1141–8.
205
The Lipid Research Clinics Coronary Primary Prevention Trial Results. II. The Relationship of Reduction in Incidence of Coronary Heart Disease to Cholesterol Lowering. Journal of the American Medical Association. 1984;251:365–74.
206
Sumner P., Vivian-Griffiths S, Boivin J, et al. The Association Between Exaggeration in Health Related Science News and Academic Press Releases: Retrospective Observational Study. British Medical Journal. 2014;349: g7015.
207
Benjamin D. J., Berger J. O., Johannesson M., et al. Redefine Statistical Significance. Nature Human Behaviour. 2018;2:6–10.
208
Baker M. 1,500 Scientists Lift the Lid on Reproducibility. Nature. 2016;533:452–4.
209
Ioannidis J. P. Contradicted and Initially Stronger Effects in Highly Cited Clinical Research. Journal of the American Medical Association. 2005;294:218–28.
210
Is Watching Sports Bad for Your Health? Here’s What New Research Says. October 2017. www.reuters.com/article/us-health-sleep-heart/too-little-sleep-or-toomuch-linked-to-risk-of-heart-disease-idUSKCN11P2DU.
211
Too Little Sleep, or Too Much, Linked to Risk of Heart Disease. September 2016. www.reuters.com/article/us-health-sleep-heart/too-little-sleep-or-too-muchlinked-to-risk-of-heart-disease-idUSKCN11P2DU.
212
Statins “May Be a Waste of Time:” Controversial Report Claims There’s NO Link Between “Bad Cholesterol” and Heart Disease. June 2016. www.dailymail.co.uk/health/article-3638162/Statins-waste-time-60s-Row-controversial-report-saysno-link-bad-cholesterol-heart-disease.html.
213
Phillips D. P., Kanter E. J., Bednarczyk B., Tastad P. L. Importance of the Lay Press in the Transmission of Medical Knowledge to the Scientific Community. New England Journal of Medicine. 1991;325:1180–3.
214
Selvaraj S., Borkar D. S., Prasad V. Media Coverage of Medical Journals: Do the Best Articles Make the News? PLOS ONE. 2014;9: e85355.
215
Dumas-Mallet E., Smith A., Boraud T., Gonon F. Poor Replication Validity of Biomedical Association Studies Reported by Newspapers. PLOS ONE. 2017;12: e0172650.
216
Òàì æå.
217
Wang M. T., Bolland M. J., Grey A. Reporting of Limitations of Observational Research. JAMA Internal Medicine. 2015;175:1571–2.
218
Dumas-Mallet, Smith, Boraud, Gonon. Poor Replication Validity.
219
Sumner, Vivian-Griffiths, Boivin, et al. Association Between Exaggeration.
220
Study: Half of the Studies You Read About in the News Are Wrong. March 2017. www.vox.com/science-and-health/2017/3/3/14792174/half-scientific-studiesnews-are-wrong.
221
Caspi A., Sugden K., Moffitt T. E., et al. Influence of Life Stress on Depression: Moderation by a Polymorphism in the 5-HTT Gene. Science. 2003;301:386–9.
222
Blendon R. J., Benson J. M., Hero J. O. Public Trust in Physicians – U. S. Medicine in International Perspective. New England Journal of Medicine. 2014;371:1570–2.
223
Newman D. Hippocrates’ Shadow: Secrets from the House of Medicine. New York: Scribner; 2009.
224
Emergency Physicians Monthly. Practicing Medicine in Hippocrates’ Shadow. January 2009. http://epmonthly.com/article/practicing-medicine-in-hippocratesshadow/.
225
“What I Did Was Awful and Disgusting”: Ex-Mt. Sinai Doctor Sentenced to 2 Years for Sexually Abusing Patients. January 2017. http://gothamist.com/2017/01/24/mt_sinai_doctor_prison.php.
226
Klein M. Officials Find NYC Hospitals Riddled with Shocking Violations. New York Post. February 10, 2018.
227
Rosenberg R. Prison for Doctor Who Drugged, Sexually Assaulted Patient. New York Post. January 23, 2017.
228
Omer S. B., Amin A. B., Limaye RJ. Communicating About Vaccines in a Fact-Resistant World. JAMA Pediatrics. 2017;171:929–30.
229
Mergler M. J., Omer S.B, Pan W. K., et al. Are Recent Medical Graduates More Skeptical of Vaccines? Vaccines (Basel). 2013;1:154–66.
230
Johnson S. B., Park H. S., Gross C. P., Yu J. B. Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival Among Patients with Curable Cancers. JAMA Oncology. 2018.
231
Hyland M., Birrell J. Government Health Warnings and the “Boomerang” Effect. Psychological Reports. 1979;44:643–7.
232
Nyhan B., Reifler J., Richey S., Freed G. L. Effective Messages in Vaccine Promotion: A Randomized Trial. Pediatrics. 2014;133: e835–42.
233
Amin A. B., Bednarczyk R. A., Ray C. E., et al. Association of Moral Values with Vaccine Hesitancy. Nature Human Behaviour. 2017;1:873–80.
234
Warraich H. J., Benson C. C., Khosa F., Leeman D. E. Diagnosis of Acute Myocardial Infarction on Computed Tomography Angiogram. Circulation. 2014;129:272–3.
235
Procacci P., Maresca M. Historical Considerations of Cardiac Pain. Pain. 1985;22:325–35.
236
Mitchell S. W. Characteristics. New York: Century; 1891.
237
De Moulin D. A Historical-Phenomenological Study of Bodily Pain in Western Man. Bulletin of the History of Medicine. 1974;48:540–70.
238
Caton D. The Secularization of Pain. Anesthesiology. 1985;62:493–501.
239
De Moulin. Historical-Phenomenological Study.
240
Buytendijk F. Over de pijn (About the Pain). 3rd ed. Utrecht-Antwerp: Aula Books; 1957.
241
Stephenson J. Veterans’ Pain a Vital Sign. Journal of the American Medical Association. 1999;281:978.
242
Jackson M. Pain: The Fifth Vital Sign: The Science and Culture of Why We Hurt. New York: Crown; 2002.
243
Fauber J. 9 of 19 Experts on Pain Panel Tied to Drug Companies. Milwaukee-Wisconsin Journal Sentinel. June 25, 2014.
244
Vila H., Jr., Smith R. A., Augustyniak M. J., et al. The Efficacy and Safety of Pain Management Before and After Implementation of Hospital-Wide Pain Management Standards: Is Patient Safety Compromised by Treatment Based Solely on Numerical Pain Ratings? Anesthesia & Analgesia. 2005;101:474–80, table of contents.
245
Krebs E. E., Gravely A., Nugent S., et al. Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients with Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial. Journal of the American Medical Association. 2018;319:872–82.
246
Levy N., Sturgess J., Mills P. “Pain as the Fifth Vital Sign” and Dependence on the “Numerical Pain Scale” Is Being Abandoned in the US: Why? British Journal of Anaesthesia. 2018;120:435–8.
247
Blanchflower DG, Oswald A. Unhappiness and Pain in Modern America: A Review Essay, and Further Evidence, on Carol Graham’s Happiness for All? National Bureau of Economic Research Working Paper Series 2017; No. 24087.
248
Harvey W. The Works of William Harvey Volume 7 (translated from Latin by Robert Willis). London: Sydenham Society; 1847.
249
Haneveld GT. [“A Sad and Painful Heart”–Andreas Vesalius as Cardiologist]. Verhandelingen – Koninklijke Academie voor Geneeskunde van België. 1993;55:683–99.
250
Eslick G D. Chest Pain: A Historical Perspective. International Journal of Cardiology. 2001;77:5–11.
251
Herrick J. An Intimate Account of My Early Experience with Coronary Thrombosis. American Heart Journal. 1944;27:1–18.
252
Pagliaro P., Gattullo D., Penna C. Nitroglycerine and Sodium Trioxodinitrate: From the Discovery to the Preconditioning Effect. Journal of Cardiovascular Medicine (Hagerstown). 2013;14:698–704.
253
Fye W. B. T. Lauder Brunton and Amyl Nitrite: A Victorian Vasodilator. Circulation. 1986;74:222–9.
254
Steinhorn B.S, Loscalzo J., Michel T. Nitroglycerin and Nitric Oxide – A Rondo of Themes in Cardiovascular Therapeutics. New England Journal of Medicine. 2015;373:277–80.
255
Ghofrani H. A., Osterloh I. H., Grimminger F. Sildenafil: From Angina to Erectile Dysfunction to Pulmonary Hypertension and Beyond. Nature Reviews Drug Discovery. 2006;5:689–702.
256
Osterloh I. How I Discovered Viagra. Cosmos. April 2015.
257
Herrick J. Intimate Account.
258
Herrick J. B. Landmark Article (JAMA 1912). Clinical Features of Sudden Obstruction of the Coronary Arteries. By James B. Herrick. Journal of the American Medical Association. 1983;250:1757–65.
259
Moore B. J., Stocks C, Owens PL. Trends in Emergency Department Visits, 2006–2014. HCUP Statistical Brief #227. Agency for Healthcare Research and Quality, Rockville, MD. www.hcup-us.ahrq.gov/reports/statbriefs/sb227-Emergency-Department-Visit-Trends.pdf. September 2017.
260
Amsterdam E. A., Kirk J. D., Bluemke D. A., et al. Testing of Low-Risk Patients Presenting to the Emergency Department with Chest Pain: A Scientific Statement from the American Heart Association. Circulation. 2010;122:1756–76.
261
Obermeyer Z., Cohn B., Wilson M… Jena A. B., Cutler D. M. Early Death After Discharge from Emergency Departments: Analysis of National US Insurance Claims Data. British Medical Journal. 2017;356: j239.
262
Ahmed A., Sorajja P., Pai A., et al. Prospective Evaluation of the Eyeball Test for Assessing Frailty in Patients with Valvular Heart Disease. Journal of the American College of Cardiology. 2016;68:2911–2.
263
Christenson J., Innes G., McKnight D., et al. A Clinical Prediction Rule for Early Discharge of Patients with Chest Pain. Annals of Emergency Medicine. 2006;47:1–10.
264
Fanaroff A. C., Rymer J. A., Goldstein S. A., Simel D. L., Newby L. K. Does This Patient with Chest Pain Have Acute Coronary Syndrome?: The Rational Clinical Examination Systematic Review. Journal of the American Medical Association. 2015;314:1955–65.
265
Obrastzow W. P., Straschesko N. D. Zur Kenntnis der Thrombose der Koronararterien des Herzens (To Note the Thrombosis of the Coronary Arteries of the Heart). Zeitschrift für klinische Medizin. 1910;71:116–32.
266
Yeh R. W., Sidney S., Chandra M., Sorel M., Selby J. V., Go AS. Population Trends in the Incidence and Outcomes of Acute Myocardial Infarction. New England Journal of Medicine. 2010;362:2155–65.
267
Òàì æå.
268
Parsons T. The Sick Role and the Role of the Physician Reconsidered. Milbank Memorial Fund Quarterly: Health and Society. 1975;53:257–78.
269
Galdas P., Cheater F., Marshall P. What Is the Role of Masculinity in White and South Asian Men’s Decisions to Seek Medical Help for Cardiac Chest Pain? Journal of Health Services Research & Policy. 2007;12:223–9.
270
French D. P., Cooper A., Weinman J. Illness Perceptions Predict Attendance at Cardiac Rehabilitation Following Acute Myocardial Infarction: A Systematic Review with Meta-Analysis. Journal of Psychosomatic Research. 2006;61:757–67.
271
Chen S.L, Tsai. J.C., Chou KR. Illness Perceptions and Adherence to Therapeutic Regimens Among Patients with Hypertension: A Structural Modeling Approach. International Journal of Nursing Studies. 2011;48:235–45.
272
Beck R. S., Daughtridge R, Sloane P. D. Physician-Patient Communication in the Primary Care Office: A Systematic Review. Journal of the American Board of Family Practice. 2002;15:25–38.
273
Egbert L. D., Battit G. E., Welch C. E., Bartlett M. K. Reduction of Postoperative Pain by Encouragement and Instruction of Patients. A Study of Doctor-Patient Rapport. New England Journal of Medicine. 1964;270:825–7.
274
Alpert J. S., Thygesen K., Antman E., Bassand J. P. Myocardial Infarction Redefined – A Consensus Document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. Journal of the American College of Cardiology. 2000;36:959–69.
275
Rahman A., Broadley S. A. Review Article: Elevated Troponin: Diagnostic Gold or Fool’s Gold? Emergency Medicine Australasia. 2014;26:125–30.
276
Autier P., Boniol M., Koechlin A., Pizot C., Boniol M. Effectiveness of and Overdiagnosis from Mammography Screening in the Netherlands: Population-Based Study. British Medical Journal. 2017;359: j5224.
277
Ilic D., Neuberger M. M., Djulbegovic M., Dahm P. Screening for Prostate Cancer. Cochrane Database of Systematic Reviews. 2013: CD004720.
278
Yudkin J. S., Montori V. M. The Epidemic of Pre-Diabetes: The Medicine and the Politics. British Medical Journal. 2014;349: g4485.
279
Moynihan R. Caution! Diagnosis Creep. Australian Prescriber. 2016;39:30–1.
280
Than M., Herbert M., Flaws D., et al. What Is an Acceptable Risk of Major Adverse Cardiac Event in Chest Pain Patients Soon After Discharge from the Emergency Department?: A Clinical Survey. International Journal of Cardiology. 2013;166:752–4.
281
Moynihan R. N., Cooke G. P., Doust J. A., Bero L., Hill S., Glasziou P. P. Expanding Disease Definitions in Guidelines and Expert Panel Ties to Industry: A Cross-Sectional Study of Common Conditions in the United States. PLOS Medicine. 2013;10: e1001500.
282
Òàì æå.
283
Upchurch C. T., Barrett E. J. Clinical Review: Screening for Coronary Artery Disease in Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism. 2012;97:1434–42.
284
Reed S, Pearson S. ICER. Choosing Wisely Recommendation Analysis: Prioritizing Opportunities for Reducing Inappropriate Care. Preoperative Stress Testing. 2016.
285
George Lakoff and Mark Johnson. Metaphors We Live By. 1st ed. Chicago, IL: University of Chicago Press; 2003.
286
Goff S. L., Mazor K. M., Ting H. H., Kleppel R., Rothberg M. B. How Cardiologists Present the Benefits of Percutaneous Coronary Interventions to Patients with Stable Angina: A Qualitative Analysis. JAMA Internal Medicine. 2014;174:1614–21.
287
The Widow Maker Heart Attack. January 2015. https://myheart.net/articles/thewidowmaker/.
288
Al-Lamee R., Thompson D., Dehbi H. M., et al. Percutaneous Coronary Intervention in Stable Angina (ORBITA): A Double-Blind, Randomised Controlled Trial. Lancet. 2018;391:31–40.
289
Badawy M. K., Deb P., Chan R., Farouque O. A Review of Radiation Protection Solutions for the Staff in the Cardiac Catheterisation Laboratory. Heart, Lung and Circulation. 2016;25:961–7.
290
CABG íàïîìèíàåò íàïèñàíèåì ñëîâî cabbage – êàïóñòà.
291
Menzoian J. O., Koshar A. L., Rodrigues N. Alexis Carrel, Rene Leriche, Jean Kunlin, and the History of Bypass Surgery. Journal of Vascular Surgery. 2011;54:571–4.
292
Head S. J., Kieser T. M., Falk V., Huysmans HA, Kappetein AP. Coronary Artery Bypass Grafting: Part 1–The Evolution over the First 50 Years. European Heart Journal. 2013;34:2862–72.
293
JD R. New Surgery for Ailing Hearts. Reader’s Digest. 71:70 1957.
294
Cobb L. A., Thomas G. I., Dillard D. H., Merendino K. A., Bruce R. A. An Evaluation of Internal-Mammary-Artery Ligation by a Double-Blind Technic. New England Journal of Medicine. 1959;260:1115–8.
295
Shroyer A. L., Grover F. L., Hattler B., et al. On-Pump versus Off-Pump Coronary-Artery Bypass Surgery. New England Journal of Medicine. 2009;361:1827–37.
296
ElBardissi A.W., Aranki S. F., Sheng S., O’Brien S.M., Greenberg C. C., Gammie J. S. Trends in Isolated Coronary Artery Bypass Grafting: An Analysis of the Society of Thoracic Surgeons Adult Cardiac Surgery Database. Journal of Thoracic and Cardiovascular Surgery. 2012;143:273–81.
297
Forssmann W. Experiments on Myself. Memoirs of a Surgeon in Germany. New York: St. Martin’s; 1974.
298
Forssmann W. Die Sondierung des rechten Herzens. Klinische Wochenschrift. 1929;8:2085–7.
299
Heiss H. W. Werner Forssmann: A German Problem with the Nobel Prize. Clinical Cardiology. 1992;15:547–9.
300
Ryan T. J. The Coronary Angiogram and Its Seminal Contributions to Cardiovascular Medicine Over Five Decades. Circulation. 2002;106:752–6.
301
Sheldon W. C. F. Mason Sones, Jr. – Stormy Petrel of Cardiology. Clinical Cardiology. 1994;17:405–7.
302
Shrager J. B. The Vineberg Procedure: The Immediate Forerunner of Coronary Artery Bypass Grafting. Annals of Thoracic Surgery. 1994;57:1354–64.
303
Sheldon. F. Mason Sones.
304
Hurst J. W., King S. B., 3rd, Greene L. In Memory of Andreas Roland Gruentzig and Margaret Anne Thornton Gruentzig. American Journal of Cardiology. 1986;57:333–6.
305
Òàì æå.
306
Barton M., Gruntzig J., Husmann M., Rosch J. Balloon Angioplasty – The Legacy of Andreas Gruntzig, M.D. (1939–1985). Frontiers in Cardiovascular Medicine. 2014; 1:15.
307
Hurst J. W. The First Coronary Angioplasty as Described by Andreas Gruentzig. American Journal of Cardiology. 1986;57:185–6.
308
Byrne R..A., Capodanno D., Mylotte D., Serruys P. W. State of the Art: 40 Years of Percutaneous Cardiac Intervention. EuroIntervention. 2017;13:621–4.
309
Gruntzig A. Transluminal Dilatation of Coronary-Artery Stenosis. Lancet. 1978;1:263.
310
Meier B. The First Patient to Undergo Coronary Angioplasty-23-Year Follow-Up. New England Journal of Medicine. 2001;344:144–5.
311
International Trade Administration. Department of Commerce. 2016 Top Markets Report: Medical Devices. Overview and Key Findings. www.trade.gov/topmarkets/pdf/Medical_Devices_Executive_Summary.pdf.
312
Psaty B. M., Boineau R., Kuller L. H., Luepker R. V. The Potential Costs of Upcoding for Heart Failure in the United States. American Journal of Cardiology. 1999;84:108–9, A9.
313
Coding in the Anti-Fraud Era. Skirt the Upcoding Spotlight. Hospital Peer Review. 1997;22:141–3.
314
Desai N. R., Bradley S. M., Parzynski C. S., et al. Appropriate Use Criteria for Coronary Revascularization and Trends in Utilization, Patient Selection, and Appropriateness of Percutaneous Coronary Intervention. Journal of the American Medical Association. 2015;314:2045–53.
315
Gupta A., Yeh R. W., Tamis-Holland J.E., et al. Implications of Public Reporting of Risk-Adjusted Mortality Following Percutaneous Coronary Intervention: Misperceptions and Potential Consequences for High-Risk Patients Including Nonsurgical Patients. JACC Cardiovascular Interventions. 2016;9:2077–85.
316
Boden W. E., O’Rourke R.A., Teo K. K., et al. Optimal Medical Therapy with or without PCI for Stable Coronary Disease. New England Journal of Medicine. 2007;356:1503–16.
317
Sedlis S. P., Hartigan P. M., Teo K. K., et al. Effect of PCI on Long-Term Survival in Patients with Stable Ischemic Heart Disease. New England Journal of Medicine. 2015;373:1937–46.
318
Al-Lamee, Thompson, Dehbi, et al. Percutaneous Coronary Intervention.
319
Carrozza J. P., Levin T. Periprocedural Complications of Percutaneous Coronary Intervention. UpToDate. Last updated February 8, 2018.
320
Fornell D. Tempering the Bioresorbable Stent Euphoria Following FDA Clearance of the Absorb. August 2016. www.dicardiology.com/content/blogs/tempering-bioresorbable-stent-euphoria-following-fda-clearance-absorb.
321
De Rosa R., Silverio A., Varricchio A., et al. Meta-Analysis Comparing Outcomes After Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents in Patients with Acute Coronary Syndromes. American Journal of Cardiology. 2018;122:61–8.
322
Lenzer J. When Is a Point of View a Conflict of Interest? British Medical Journal. 2016;355: i6194.
323
de Alencar Neto J. N. Morphine, Oxygen, Nitrates, and Mortality Reducing Pharmacological Treatment for Acute Coronary Syndrome: An Evidence-Based Review. Cureus. 2018;10: e2114.
324
Gouda P., Bainey K., Welsh R. The Demise of Morphine Oxygen Nitroglycerin Aspirin (MONA). Canadian Journal of Cardiology. 2016;32:1578 e7.
325
Hayes S. N., Kim E. S.H., Saw J., et al. Spontaneous Coronary Artery Dissection: Current State of the Science: A Scientific Statement From the American Heart Association. Circulation. 2018;137: e523-e57.
326
Lerner D. J., Kannel W. B. Patterns of Coronary Heart Disease Morbidity and Mortality in the Sexes: A 26-Year Follow-Up of the Framingham Population. American Heart Journal. 1986;111:383–90.
327
Mehta L. S., Watson K. E., Barac A., et al. Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association. Circulation. 2018;137: e30-e66.
328
Mosca L., Hammond G., Mochari-Greenberger H., et al. Fifteen-Year Trends in Awareness of Heart Disease in Women: Results of a 2012 American Heart Association National Survey. Circulation. 2013;127:1254–63, e1–29.
329
Pope J. H., Aufderheide T. P., Ruthazer R., et al. Missed Diagnoses of Acute Cardiac Ischemia in the Emergency Department. New England Journal of Medicine. 2000;342:1163–70.
330
Bugiardini R., Ricci B., Cenko E., et al. Delayed Care and Mortality Among Women and Men with Myocardial Infarction. Journal of the American Heart Association. 2017;6.
331
Zwas D. R. Redressing the Red Dress: Rethinking the Campaign. Circulation. 2018;137:763–5.
332
Kragholm K., Halim S. A., Yang Q., et al. Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non-ST-Segment Elevation Acute Coronary Syndrome Patients: Insights From Clinical Trials Over 17 Years. Circulation: Cardiovascular Quality and Outcomes. 2015;8:357–67.
333
Rosenman R. H., Brand R. J., Jenkins D., Friedman M., Straus R., Wurm M. Coronary Heart Disease in Western Collaborative Group Study. Final Follow-Up Experience of 8 1/2 Years. Journal of the American Medical Association. 1975;233:872–7.
334
Keys A., Taylor H. L., Blackburn H., Brozek J., Anderson J. T., Simonson E. Coronary Heart Disease Among Minnesota Business and Professional Men Followed Fifteen Years. Circulation. 1963;28:381–95.
335
Chapman J. M., Massey F. J., Jr. The Interrelationship of Serum Cholesterol, Hypertension, Body Weight, and Risk of Coronary Disease. Results of the First Ten Years’ Follow-up in the Los Angeles Heart Study. Journal of Chronic Diseases. 1964;17:933–49.
336
Chen G., Levy D. Contributions of the Framingham Heart Study to the Epidemiology of Coronary Heart Disease. JAMA Cardiology. 2016;1:825–30.
337
Epstein F. H., Ostrander L. D., Jr., Johnson bc, et al. Epidemiological Studies of Cardiovascular Disease in a Total Community – Tecumseh, Michigan. Annals of Internal Medicine. 1965;62:1170–87.
338
Merkatz R. B., Temple R., Subel S., Feiden K, Kessler DA. Women in Clinical Trials of New Drugs. A Change in Food and Drug Administration Policy. The Working Group on Women in Clinical Trials. New England Journal of Medicine. 1993;329:292–6.
339
McCormick K.M., Bunting S. M. Application of Feminist Theory in Nursing Research: The Case of Women and Cardiovascular Disease. Health Care of Women International. 2002;23:820–34.
340
Albrektsen G., Heuch I., Lochen M. L., et al. Lifelong Gender Gap in Risk of Incident Myocardial Infarction: The Tromso Study. JAMA Internal Medicine. 2016;176:1673–9.
341
Berg J., Bjorck L., Nielsen S., Lappas G., Rosengren A. Sex Differences in Survival After Myocardial Infarction in Sweden, 1987–2010. Heart. 2017;103:1625–30.
342
Ricci B., Cenko E., Vasiljevic Z., et al. Acute Coronary Syndrome: The Risk to Young Women. Journal of the American Heart Association. 2017;6.
343
Wyckoff J. Heart Disease: Points Every Nurse Should Know About It. American Journal of Nursing. 1924;24:529–32.
344
White P. D. Important Clues in Cardiovascular Diagnosis. New England Journal of Medicine. 1942;227:980–4.
345
Hamilton B. E. The Care of a Cardiac Patient During Pregnancy. American Journal of Nursing. 1927;27:173–7.
346
Upton N. B. Home Adjustments in Chronic Heart Disease. New England Journal of Medicine. 1929;200:5–7.
347
Jones R. L. A Case Study: Mitral Stenosis with Auricular Fibrillation. American Journal of Nursing. 1938;38:1151–6.
348
Chinn P. L., Wheeler C. E. Feminism and Nursing. Nursing Outlook. 1985;33:74–7.
349
Nichols FH. History of the Women’s Health Movement in the 20th Century. Journal of Obstetric, Gynecologic, & Neonatal Nursing. 2000;29:56–64.
350
Miller CL, Kollauf CR. Evolution of Information on Women and Heart Disease 1957–2000: A Review of Archival Records and Secular Literature. Heart & Lung. 2002;31:253–61.
351
King K. M., Paul P. A Historical Review of the Depiction of Women in Cardiovascular Literature. Western Journal of Nursing Research. 1996;18:89–101.
352
Thomas JL, Braus PA. Coronary Artery Disease in Women. A Historical Perspective. Archives of Internal Medicine. 1998;158:333–7.
353
Pope TP. Maternal Instinct Is Wired into the Brain. March 2008. https://well.blogs.nytimes.com/2008/03/07/maternal-instinct-is-wired-into-the-brain/.
354
AARP. National Alliance for Caregiving and AARP. Caregiving in the U.S. www.caregiving.org/wp-content/uploads/2015/05/2015_CaregivingintheUS_Final-Report-June-4_WEB.pdf.2015.
355
Adelman R. D., Tmanova L. L., Delgado D., Dion S., Lachs M. S. Caregiver Burden: A Clinical Review. Journal of the American Medical Association. 2014;311:1052–60.
356
Granger BB, Ekman I, Granger CB, et al. Adherence to Medication According to Sex and Age in the CHARM Programme. European Journal of Heart Failure. 2009;11:1092–8.
357
Pilgrim T., Heg D., Tal K., et al. Age-and Gender-Related Disparities in Primary Percutaneous Coronary Interventions for Acute ST-Segment Elevation Myocardial Infarction. PLOS ONE. 2015;10: e0137047.
358
Swaminathan R. V., Feldman D. N., Pashun R. A., et al. Gender Differences in In-Hospital Outcomes After Coronary Artery Bypass Grafting. American Journal of Cardiology. 2016;118:362–8.
359
Hinohara TT, Al-Khalidi HR, Fordyce CB, et al. Impact of Regional Systems of Care on Disparities in Care Among Female and Black Patients Presenting with ST-Segment-Elevation Myocardial Infarction. Journal of the American Heart Association. 2017;6.
360
Singh JA, Lu X, Ibrahim S, Cram P. Trends in and Disparities for Acute Myocardial Infarction: An Analysis of Medicare Claims Data from 1992 to 2010. BMC Medicine. 2014;12:190.
361
O’Keefe-McCarthy S. Women’s Experiences of Cardiac Pain: A Review of the Literature. Canadian Journal of Cardiovascular Nursing. 2008;18:18–25.
362
Hart P. L. Women’s Perceptions of Coronary Heart Disease: An Integrative Review. Journal of Cardiovascular Nursing. 2005;20:170–6.
363
Kirchberger I., Heier M., Wende R., von Scheidt W., Meisinger C. The Patient’s Interpretation of Myocardial Infarction Symptoms and Its Role in the Decision Process to Seek Treatment: The MONICA/KORA Myocardial Infarction Registry. Clinical Research in Cardiology. 2012;101:909–16.
364
Bugiardini, Ricci, Cenko, et al. Delayed Care.
365
Davis L. L. A Qualitative Study of Symptom Experiences of Women with Acute Coronary Syndrome. Journal of Cardiovascular Nursing. 2017;32:488–95.
366
Òàì æå.
367
From A. M., Prasad A., Pellikka P.A, McCully R. B. Are Some False-Positive Stress Echocardiograms a Forme Fruste Variety of Apical Ballooning Syndrome? American Journal of Cardiology. 2009;103:1434–8.
368
Fitzgerald B. T., Scalia W. M., Scalia G. M. Female False Positive Exercise Stress ECG Testing-Fact Verses Fiction. Heart, Lung and Circulation. 2018.
369
Canto J. G., Rogers W. J., Goldberg R. J., et al. Association of Age and Sex with Myocardial Infarction Symptom Presentation and In-Hospital Mortality. Journal of the American Medical Association. 2012;307:813–22.
370
Lichtman J. H., Leifheit E. C., Safdar B., et al. Sex Differences in the Presentation and Perception of Symptoms Among Young Patients with Myocardial Infarction: Evidence from the VIRGO Study (Variation in Recovery: Role of Gender on Outcomes of Young AMI Patients). Circulation. 2018;137:781–90.
371
Galdas P. M., Johnson J. L., Percy M. E., Ratner P. A. Help Seeking for Cardiac Symptoms: Beyond the Masculine-Feminine Binary. Social Science & Medicine. 2010;71:18–24.
372
Òàì æå.
373
Canto, Rogers, Goldberg, et al. Association of Age and Sex.
374
Abstract of the Bill of Mortality for the Town of Boston. New England Journal of Medicine and Surgery. 1812:1:320–1.
375
Arias E., Heron M., Xu J. United States Life Tables, 2014. National Vital Statistics Reports. 2017;66:1–64.
376
Amos A., Haglund M. From Social Taboo to “Torch of Freedom”: The Marketing of Cigarettes to Women. Tobacco Control. 2000;9:3–8.
377
McCormick, Bunting. Application of Feminist Theory.
378
Òàì æå.
379
Manson J. E., Martin K. A. Clinical Practice. Postmenopausal Hormone-Replacement Therapy. New England Journal of Medicine. 2001;345:34–40.
380
Stampfer M. J., Colditz G. A., Willett W. C., et al. Postmenopausal Estrogen Therapy and Cardiovascular Disease. Ten-Year Follow-Up from the Nurses’ Health Study. New England Journal of Medicine. 1991;325:756–62.
381
Effects of Estrogen or Estrogen/Progestin Regimens on Heart Disease Risk Factors in Postmenopausal Women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. Journal of the American Medical Association. 1995;273:199–208.
382
Hodis H. N., Mack W. J., Lobo R. A., et al. Estrogen in the Prevention of Atherosclerosis. A Randomized, Double-Blind, Placebo-Controlled Trial. Annals of Internal Medicine. 2001;135:939–53.
383
Muka T., Oliver-Williams C., Kunutsor S., et al. Association of Age at Onset of Menopause and Time Since Onset of Menopause with Cardiovascular Outcomes, Intermediate Vascular Traits, and All-Cause Mortality: A Systematic Review and Meta-Analysis. JAMA Cardiology. 2016;1:767–76.
384
Hulley S., Grady D., Bush T., et al. Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. Journal of the American Medical Association. 1998;280:605–13.
385
Rossouw J. E., Anderson G. L., Prentice R. L., et al. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results from the Women’s Health Initiative Randomized Controlled Trial. Journal of the American Medical Association. 2002;288:321–33.
386
Ioannidis J. P. Contradicted and Initially Stronger Effects in Highly Cited Clinical Research. Journal of the American Medical Association. 2005;294:218–28.
387
Gooren L. J., Wierckx K., Giltay E. J. Cardiovascular Disease in Transsexual Persons Treated with Cross-Sex Hormones: Reversal of the Traditional Sex Difference in Cardiovascular Disease Pattern. European Journal of Endocrinology. 2014;170:809–19.
388
Kannel W. B., D’Agostino R.B., Wilson P. W., Belanger A. J., Gagnon D. R. Diabetes, Fibrinogen, and Risk of Cardiovascular Disease: The Framingham Experience. American Heart Journal. 1990;120:672–6.
389
Anand S. S., Islam S., Rosengren A., et al. Risk Factors for Myocardial Infarction in Women and Men: Insights from the INTERHEART Study. European Heart Journal. 2008;29:932–40.
390
Puymirat E., Simon T., Steg P. G., et al. Association of Changes in Clinical Characteristics and Management with Improvement in Survival Among Patients with ST-Elevation Myocardial Infarction. Journal of the American Medical Association. 2012; 308:998–1006.
391
Lenz W. A Short History of Thalidomide Embryopathy. Teratology. 1988;38:203–15.
392
Watts G. Frances Oldham Kelsey. Lancet. 2015;386:1334.
393
Elkayam U., Goland S., Pieper P. G., Silverside C. K. High-Risk Cardiac Disease in Pregnancy: Part I. Journal of the American College of Cardiology. 2016;68:396–410.
394
Arany Z., Elkayam U. Peripartum Cardiomyopathy. Circulation. 2016;133:1397–409.
395
Bennett M. R. Development of the Concept of Mind. Australian and New Zealand Journal of Psychiatry. 2007;41:943–56.
396
Jackson M. The Stress of Life: A Modern Complaint? Lancet. 2014;383:300–1.
397
English Mechanic and World of Science. No. 366. Increase of Heart-Disease. London: Mechanics; March 29, 1872.
398
Jackson. The Stress of Life.
399
Beck J. “Americanitis”: The Disease of Living Too Fast. Atlantic. March 2016.
400
Jackson. The Stress of Life.
401
Osler W. Lectures on Angina Pectoris and Allied States. New York: D. Appleton and Company; 1897.
402
Keys, Taylor, Blackburn, Brozek, Anderson, Simonson. Coronary Heart Disease.
403
Huffman J. C., Pollack M. H., Stern T. A. Panic Disorder and Chest Pain: Mechanisms, Morbidity, and Management. Primary Care Companion to the Journal of Clinical Psychiatry. 2002;4:54–62.
404
Demiryoguran N. S., Karcioglu O., Topacoglu H., et al. Anxiety Disorder in Patients with Non-Specific Chest Pain in the Emergency Setting. Emergency Medicine Journal. 2006;23:99–102.
405
Warraich H. J., Buxton A. E., Kociol R. D. Macroscopic T-Wave Alternans in a Patient with Takotsubo Cardiomyopathy and QT Prolongation. Heart Rhythm. 2014;11:1848–9.
406
Sato T. H., Uchida T., Dote K., Ishihara M. Takotsubo-Like Left Ventricular Dysfunction Due to Multivessel Coronary Spasm. In: Kodama K, Haze K, Hori M, eds. Clinical Aspect of Myocardial Injury: From Ischemia to Heart Failure. Tokyo, Japan: Kagakuhyoronsha Publishing Co:56–64. 1990.
407
Wallstrom S., Ulin K., Maatta S., Omerovic E., Ekman I. Impact of Long-Term Stress in Takotsubo Syndrome: Experience of Patients. European Journal of Cardiovascular Nursing. 2016;15:522–8.
408
Nesse R. M., Young E. A. Evolutionary Origins and Functions of the Stress Response. In: Encyclopedia of Stress. Amsterdam: Elsevier; 2000.
409
Kim N. H., Lee G., Sherer N. A., Martini K. M., Goldenfeld N., Kuhlman T. E. Real– Time Transposable Element Activity in Individual Live Cells. Proceedings of the National Academy of Sciences of the United States of America. 2016;113:7278–83.
410
Koolhaas J. M., Bartolomucci A., Buwalda B., et al. Stress Revisited: A Critical Evaluation of the Stress Concept. Neuroscience & Biobehavioral Reviews. 2011;35:1291–301.
411
Pelliccia F., Kaski J. C., Crea F., Camici P. G. Pathophysiology of Takotsubo Syndrome. Circulation. 2017;135:2426–41.
412
Wittstein IS, Thiemann DR, Lima JA, et al. Neurohumoral Features of Myocardial Stunning Due to Sudden Emotional Stress. New England Journal of Medicine. 2005;352:539–48.
413
Ghadri JR, Sarcon A, Diekmann J, et al. Happy Heart Syndrome: Role of Positive Emotional Stress in Takotsubo Syndrome. European Heart Journal. 2016;37:2823–9.
414
Saposnik G., Baibergenova A., Dang J., Hachinski V. Does a Birthday Predispose to Vascular Events? Neurology. 2006;67:300–4.
415
Ghadri, Sarcon, Diekmann, et al. Happy Heart Syndrome.
416
Gross M. Chronic Stress Means We’re Always on the Hunt. Current Biology. 2014;24: R405–8.
417
Foss B., Dyrstad S. M. Stress in Obesity: Cause or Consequence? Medical Hypotheses. 2011;77:7–10.
418
Hu B., Liu X., Yin S., Fan H., Feng F., Yuan J. Effects of Psychological Stress on Hypertension in Middle-Aged Chinese: A Cross-Sectional Study. PLOS ONE. 2015;10: e0129163.
419
Kelly S. J., Ismail M. Stress and Type 2 Diabetes: A Review of How Stress Contributes to the Development of Type 2 Diabetes. Annual Review of Public Health. 2015; 36:441–62.
420
Roohafza H., Kabir A., Sadeghi M., et al. Stress as a Risk Factor for Noncompliance with Treatment Regimens in Patients with Diabetes and Hypertension. ARYA Atherosclerosis. 2016;12:166–71.
421
Hu, Liu, Yin, Fan, Feng, Yuan. Effects of Psychological Stress.
422
Yusuf S., Hawken S., Ounpuu S., et al. Effect of Potentially Modifiable Risk Factors Associated with Myocardial Infarction in 52 Countries (the INTERHEART Study): Case-Control Study. Lancet. 2004;364:937–52.
423
Vaccarino V., Sullivan S., Hammadah M., et al. Mental Stress-Induced-Myocardial Ischemia in Young Patients with Recent Myocardial Infarction: Sex Differences and Mechanisms. Circulation. 2018;137:794–805.
424
Chang S. C., Glymour M., Cornelis M., et al. Social Integration and Reduced Risk of Coronary Heart Disease in Women: The Role of Lifestyle Behaviors. Circulation Research. 2017;120:1927–37.
425
Selye H. The Evolution of the Stress Concept. American Scientist. 1973;61:692–9.
426
Buccheri D., Zambelli G. The Link Between Spontaneous Coronary Artery Dissection and Takotsubo Cardiomyopathy: Analysis of the Published Cases. Journal of Thoracic Disease. 2017;9:5489–92.
427
Jagsi R., Biga C., Poppas A., et al. Work Activities and Compensation of Male and Female Cardiologists. Journal of the American College of Cardiology. 2016;67:529–41.
428
Derose K. P., Hays R. D., McCaffrey D.F., Baker D. W. Does Physician Gender Affect Satisfaction of Men and Women Visiting the Emergency Department? Journal of General Internal Medicine. 2001;16:218–26.
429
Phillips M. D., Lowe M. J., Lurito J. T., Dzemidzic M., Mathews V. P. Temporal Lobe Activation Demonstrates Sex-Based Differences During Passive Listening. Radiology. 2001;220:202–7.
430
Aloysio Luigi Galvani (1737–1798) Discoverer of Animal Electricity. Journal of the American Medical Association. 1967;201:626–7.
431
Sengupta B., Stemmler M. B. Power Consumption During Neuronal Computation. Proceedings of the IEEE 2014;102:738–50.
432
Could You Charge an iPhone with the Electricity in Your Brain? August 2015. https://gizmodo.com/could-you-charge-an-iphone-with-the-electricity-inyour-1722569935.
433
Fye W. B. A History of the Origin, Evolution, and Impact of Electrocardiography. American Journal of Cardiology. 1994;73:937–49.
434
Fye W. B. Disorders of the Heartbeat: A Historical Overview from Antiquity to the Mid-20th Century. American Journal of Cardiology. 1993;72:1055–70.
435
Goldberger Z. D., Whiting S. M., Howell J. D. The Heartfelt Music of Ludwig van Beethoven. Perspectives in Biology and Medicine. 2014;57:285–94.
436
Perman E. Successful Cardiac Resuscitation with Electricity in the 18th Century? British Medical Journal. 1978;2:1770–1.
437
Kite C. An Essay on the Recovery of the Apparently Dead. London: C. Dilly; 1788.
438
Nuland S. How We Die: Reflections of Life’s Final Chapter. New York: Knopf; 1994.
439
Beck C. S., Pritchard W. H., Feil H. S. Ventricular Fibrillation of Long Duration Abolished by Electric Shock. Journal of the American Medical Association. 1947;135:985.
440
Cohen S. I. Resuscitation great. Paul M. Zoll, M.D. – The Father of “Modern” Electrotherapy and Innovator of Pharmacotherapy for Life-Threatening Cardiac Arrhythmias. Resuscitation. 2007;73:178–85.
441
Cohen S. Paul Zoll, MD: The Pioneer Whose Discoveries Prevent Sudden Death. Salem, NH: Free People Publishing; 2014.
442
Zoll P. M., Linenthal A. J., Gibson W., Paul M. H., Norman L. R. Termination of Ventricular Fibrillation in Man by Externally Applied Electric Countershock. New England Journal of Medicine. 1956;254:727–32.
443
Cakulev I., Efimov I. R., Waldo A. L. Cardioversion: Past, Present, and Future. Circulation. 2009;120:1623–32.
444
Cuculich P. S., Schill M. R., Kashani R., et al. Noninvasive Cardiac Radiation for Ablation of Ventricular Tachycardia. New England Journal of Medicine. 2017;377:2325–36.
445
Desai N. R., Bourdillon P. M., Parzynski C. S., et al. Association of the U. S. Department of Justice Investigation of Implantable Cardioverter-Defibrillators and Devices Not Meeting the Medicare National Coverage Determination, 2007–2015. Journal of the American Medical Association. 2018;320:63–71.
446
Shen L., Jhund P. S., Petrie M. C., et al. Declining Risk of Sudden Death in Heart Failure. New England Journal of Medicine. 2017;377:41–51.
447
Kober L., Thune J. J., Nielsen J. C., et al. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. New England Journal of Medicine. 2016;375:1221–30.
448
Goldstein NE, Lampert R, Bradley E, Lynn J, Krumholz HM. Management of Implantable Cardioverter Defibrillators in End-of-Life Care. Annals of Internal Medicine. 2004;141:835–8.
449
Goldstein N. E., Mehta D., Siddiqui S., et al. “That’s Like an Act of Suicide” Patients’ Attitudes Toward Deactivation of Implantable Defibrillators. Journal of General Internal Medicine. 2008;23 Suppl 1:7–12.
450
Zoll P. M. Resuscitation of the Heart in Ventricular Standstill by External Electric Stimulation. New England Journal of Medicine. 1952;247:768–71.
451
Pycroft L., Aziz T. Z. Security of Implantable Medical Devices with Wireless Connections: The Dangers of Cyber-Attacks. Expert Review of Medical Devices. 2018; 15:403–6.
452
Dyer O. Abbott Laboratories Offers Fix for 745 000 Pacemakers Vulnerable to Hacking. British Medical Journal. 2017;358: j4190.
453
de Moor J. S., Mariotto A. B., Parry C., et al. Cancer Survivors in the United States: Prevalence Across the Survivorship Trajectory and Implications for Care. Cancer Epidemiology, Biomarkers & Prevention. 2013;22:561–70.
454
Drake N. When Hubble Stared at Nothing for 100 Hours. National Geographic. April 2015.
455
Jaiswal S., Fontanillas P., Flannick J., et al. Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes. New England Journal of Medicine. 2014;371:2488–98.
456
Stockmann C., Hersh A. L., Sherwin C. M., Spigarelli M. G. Alignment of United States Funding for Cardiovascular Disease Research with Deaths, Years of Life Lost, and Hospitalizations. International Journal of Cardiology. 2014;172: e19–21.
457
Okwuosa T. M., Anzevino S., Rao R. Cardiovascular Disease in Cancer Survivors. Postgraduate Medical Journal. 2017;93:82–90.
458
Steele C. B., Thomas C. C., Henley S. J., et al. Vital Signs: Trends in Incidence of Cancers Associated with Overweight and Obesity-United States, 2005–2014. Morbidity and Mortality Weekly Report. 2017;66:1052–8.
459
Friedenreich C. M., Shaw E., Neilson H. K., Brenner D. R. Epidemiology and Biology of Physical Activity and Cancer Recurrence. Journal of Molecular Medicine. (Berlin). 2017;95:1029–41.
460
Holmes M. D., Chen W. Y., Feskanich D., Kroenke C. H., Colditz G. A. Physical Activity and Survival After Breast Cancer Diagnosis. Journal of the American Medical Association. 2005;293:2479–86.
461
Hua X., Phipps A. I., Burnett-Hartman AN, et al. Timing of Aspirin and Other Nonsteroidal Anti-Inflammatory Drug Use Among Patients with Colorectal Cancer in Relation to Tumor Markers and Survival. Journal of Clinical Oncology. 2017;35:2806–13.
462
Omer Z. B., Hwang E. S., Esserman L. J., Howe R., Ozanne E. M. Impact of Ductal Carcinoma In Situ Terminology on Patient Treatment Preferences. Journal of the American Medical Association. Internal Medicine. 2013;173:1830–1.
463
Pentagon Gets ISIS Metaphor Wrong, Critics Say. January 2016. www.npr.org/2016/01/26/464399975/how-to-keep-isis-from-spreading-is-still-up-for-debate.
464
Greene S. J., Butler J., Albert N. M., et al. Medical Therapy for Heart Failure with Reduced Ejection Fraction: The CHAMP-HF Registry. Journal of the American College of Cardiology. 2018;72:351–66.
465
Warraich H. Failing Heart Failure Patients. New York Times. August 2015.
466
Thomson J. G. Provisional Report on the Autopsy of L. W. (Louis Washkansky). South African Medical Journal. 1967;41:1277–8.
467
Kirklin J. K., Pagani F. D., Kormos R. L., et al. Eighth Annual INTERMACS Report: Special Focus on Framing the Impact of Adverse Events. Journal of Heart and Lung Transplantation. 2017;36:1080–6.
468
Warraich H. J., Kaltenbach L. A., Fonarow G. C., Peterson E. D., Wang TY. Adverse Change in Employment Status After Acute Myocardial Infarction: Analysis From the TRANSLATE-ACS Study. Circulation: Cardiovascular Quality and Outcomes. 2018;11: e004528.
469
Cooley D. A. Some Thoughts About the Historic Events That Led to the First Clinical Implantation of a Total Artificial Heart. Texas Heart Institute Journal. 2013;40:117–9.
470
Altman L. The Feud. New York Times. 2007.
471
Maugh T. Denton Cooley, Texas Surgeon Who Performed First Successful Heart Transplant in U.S., Dies at 96. Los Angeles Times. 2016.
472
A Bitter Feud: Two Great Surgeons at War over the Human Heart. Life. April 1970.
473
Cooley. Some Thoughts About the Historic Events.
474
Altman L. The Feud.
475
Òàì æå.
476
Dr. Denton Cooley at 95: The Legend Speaks in a Video Interview. July 2016. www.houstonchronicle.com/local/prognosis/article/Cooley-at-95-Some-tidbits-froman-interview-8387536.php.
477
Cooley D. 10,000 Hearts: A Surgeon’s Memoir. Austin: Briscoe Center for American History, University of Texas; 2012.
478
Dr. Denton Cooley at 95.
479
Maugh T. Denton Cooley, Texas Surgeon.
480
Miller L. W., Rogers J. G. Evolution of Left Ventricular Assist Device Therapy for Advanced Heart Failure: A Review. JAMA Cardiology. 2018;3:650–8.
481
Jakovljevic D. G., Yacoub M. H., Schueler S., et al. Left Ventricular Assist Device as a Bridge to Recovery for Patients with Advanced Heart Failure. Journal of the American College of Cardiology. 2017;69:1924–33.
482
McIlvennan C.K., Wordingham S. E., Allen L. A., et al. Deactivation of Left Ventricular Assist Devices: Differing Perspectives of Cardiology and Hospice/Palliative Medicine Clinicians. Journal of Cardiac Failure. 2017;23:708–12.
483
Diop M. S., Rudolph J. L., Zimmerman KM, Richter M. A., Skarf L. M. Palliative Care Interventions for Patients with Heart Failure: A Systematic Review and Meta-Analysis. Journal of Palliative Medicine. 2017;20:84–92.
484
Warraich H. J., Hernandez A. F., Allen L. A. How Medicine Has Changed the End of Life for Patients with Cardiovascular Disease. Journal of the American College of Cardiology. 2017;70:1276–89.
485
Warraich H. J., Mentz R. J., Hernandez A. F. Paving a Better Path for Patients Dying of Heart Disease. Circulation. 2018;137:1216–7.
486
Doctor Considers the Pitfalls of Extending Life and Prolonging Death. January 2017. www.npr.org/sections/health-shots/2017/01/30/512426568/doctorconsiders-the-pitfalls-of-extending-life-and-prolonging-death.
487
Warraich, Hernandez, Allen. How Medicine Has Changed the End.
488
Goldstein N.E, Lampert R., Bradley E., Lynn J., Krumholz H. M. Management of Implantable Cardioverter Defibrillators in End-of-Life Care. Annals of Internal Medicine. 2004;141:835–8.
489
Goldstein N. E., Mehta D., Siddiqui S., et al. “That’s Like an Act of Suicide” Patients’ Attitudes Toward Deactivation of Implantable Defibrillators. Journal of General Internal Medicine. 2008;23 Suppl 1:7–12.
490
Singh G. K., Siahpush M., Azuine R. E., Williams S. D. Widening Socioeconomic and Racial Disparities in Cardiovascular Disease Mortality in the United States, 1969–2013. International Journal of MCH and AIDS. 2015;3:106–18.
491
Rosenson R. S., Hegele R. A., Fazio S., Cannon CP. The Evolving Future of PCSK9 Inhibitors. Journal of the American College of Cardiology. 2018;72:314–29.
492
Ray K. K., Landmesser U., Leiter L. A., et al. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. New England Journal of Medicine. 2017;376:1430–40.
493
Singh, Siahpush, Azuine, Williams. Widening Socioeconomic and Racial Disparities.
 Âåðíóòüñÿ ê ïðîñìîòðó êíèãè
|
×èòàòü êíèãó « Ñåðäöå, êîòîðîå ìû íå çíàåì. Èñòîðèÿ âàæíåéøèõ îòêðûòèé è áóäóùåå ëå÷åíèÿ ñåðäå÷íî-ñîñóäèñòûõ çàáîëåâàíèé »
© 2020 LoveRead.ec - ýëåêòðîííàÿ áèáëèîòåêà â êîòîðîé ìîæíî
÷èòàòü îíëàéí êíèãè áåñïëàòíî
.
Âñå ìàòåðèàëû âçÿòû èç îòêðûòûõ èñòî÷íèêîâ è ïðåäñòàâëåíû èñêëþ÷èòåëüíî â îçíàêîìèòåëüíûõ öåëÿõ.
Âñå ïðàâà íà êíèãó Ñåðäöå, êîòîðîå ìû íå çíàåì. Èñòîðèÿ âàæíåéøèõ îòêðûòèé è áóäóùåå ëå÷åíèÿ ñåðäå÷íî-ñîñóäèñòûõ çàáîëåâàíèé
ïðèíàäëåæàò àâòîðó Õàéäåð Âàððàé÷ è èçäàòåëüñòâàì.